Holen Sie sich die Stockscreener-App
0.4802
4.40%
-0.0221
Schlusskurs vom Vortag:
$0.5023
Offen:
$0.51
24-Stunden-Volumen:
359.82K
Relative Volume:
0.21
Marktkapitalisierung:
$62.96M
Einnahmen:
Nettoeinkommen (Verlust:
$-25.91M
KGV:
-1.9078
EPS:
-0.2517
Netto-Cashflow:
$-22.73M
1W Leistung:
-3.24%
1M Leistung:
-29.72%
6M Leistung:
-53.38%
1J Leistung:
-59.98%
1-Tages-Spanne:
$0.48
$0.52
1-Wochen-Bereich:
$0.49
$0.5229
52-Wochen-Spanne:
$0.4414
$1.32
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Firmenname
Oncolytics Biotech Inc
Sektor
Branche
Telefon
(403) 670-7377
Adresse
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.4802 | 62.96M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
512.88 | 130.00B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
801.46 | 82.51B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
197.28 | 78.76B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.00 | 54.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.06 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Eingeleitet | Lake Street | Buy |
| 2022-10-06 | Eingeleitet | Maxim Group | Buy |
| 2021-02-17 | Eingeleitet | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
Form 8K Oncolytics Biotech Inc. For: 20 October By Investing.com - Investing.com Nigeria
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Form 8K Oncolytics Biotech Inc. For: 20 October By Investing.com - Investing.com India
A colon cancer trial with 30 patients per arm anchors Oncolytics (ONCY)'s planned congress poster. - Stock Titan
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Patent protection for Oncolytics’ cancer therapy could extend into the late 2040s. - Stock Titan
Form DEF 14A CG Oncology Inc For: 11 October By Investing.com - Investing.com Nigeria
Form DEF 14A CG Oncology Inc For: 11 October By Investing.com - Investing.com South Africa
Form DEF 14A CG Oncology Inc For: 11 October By Investing.com - Investing.com India
Oncolytics Biotech Announces November 19, 2026 Annual Stockholder Meeting and Proxy Details - Kalkine Media
Two directors aren't standing for reelection at Oncolytics Biotech (ONCY)'s November 19 meeting. - Stock Titan
TRex Bio Files for Nasdaq IPO - Yahoo! Finance Canada
Oncolytics Biotech (Nasdaq:ONCY)Stock Analysis - Simply Wall Street
Pyxis Oncology stock falls on public offering announcement - Yahoo! Finance Canada
Form 8K Oncolytics Biotech Inc. For: 29 September By Investing.com - Investing.com South Africa
Form 8K Oncolytics Biotech Inc. For: 29 September By Investing.com - Investing.com Nigeria
Form 8K Oncolytics Biotech Inc. For: 29 September By Investing.com - Investing.com Canada
Form 8K Oncolytics Biotech Inc. For: 28 September By Investing.com - Investing.com Nigeria
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech (NasdaqCM:ONCY) Stock Forecast & Analyst Predictions - Simply Wall Street
Stocks In Play - baystreet.ca
Oncolytics Biotech Stock Price Forecast. Should You Buy ONCY? - StockInvest.us
Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer - marketscreener.com
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics (ONCY) Reports Promising Preclinical Data on Pelareor - GuruFocus
Oncolytics reports preclinical data on pelareorep with RAS inhibitor - investing.com
Oncolytics reports preclinical data on pelareorep with RAS inhibitor By Investing.com - Investing.com India
An experimental cancer treatment combination reduced tumor growth in early tests - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Oncolytics Biotech Inc.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Zacks Research Issues Pessimistic Forecast for ONCY Earnings - MarketBeat
ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC - Yahoo Finance
Could Oncolytics Biotech (TSX:ONC) Reach Its Next Clinical Milestone? - Kalkine Media
Can Oncolytics Biotech (TSX:ONC) Unlock Its Next Catalyst? - Kalkine Media
HC Wainwright Has Bearish Estimate for ONCY FY2026 Earnings - MarketBeat
ONCY Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat
H.C. Wainwright cuts Oncolytics Biotech price target to $5 on pipeline shift - Investing.com Canada
H.C. Wainwright cuts Oncolytics Biotech price target to $5 on pipeline shift - Investing.com
H.C. Wainwright cuts Oncolytics Biotech price target to $5 on pipeline shift - Investing.com
H.C. Wainwright Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials - Yahoo Finance
BRIEF-Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer - Bitget
Oncolytics Biotech (ONCY) Advances Pelareorep Trial with Positiv - GuruFocus
Finanzdaten der Oncolytics Biotech Inc-Aktie (ONCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oncolytics Biotech Inc-Aktie (ONCY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Mar 12 '26 |
Buy |
0.96 |
5,050 |
4,848 |
114,050 |
| Andrews Patricia S | Director |
Feb 12 '26 |
Buy |
0.86 |
35,400 |
30,292 |
78,128 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Kelly Jared | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.84 |
29,500 |
24,839 |
109,000 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
1.49%
2.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):